Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
PrEP Use Among Gay and Bi Men Hits a New High

A third of at-risk gay and bi men are now using Truvada for HIV prevention, the CDC says.

Published
23 hours ago
From
Poz
On-Demand PrEP With TDF/FTC Not Associated With Clinically Relevant Decline in Kidney Function

On-demand pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is not associated with a significant relevant in kidney function, especially among young people with low pill use and high baseline estimated glomerular filtration rate, investigators in France found.

Published
20 March 2019
From
Contagion Live
Urine test can provide accurate point-of-care results about PrEP adherece

A point-of-care urine test can accurately determine if a person if adherent to tenofovir-based pre-exposure prophylaxis (PrEP), according to research presented to the recent Conference on Retroviruses

Published
19 March 2019
By
Michael Carter
LGBT+ health adviser urges Britain to make HIV-prevention drug free

Britain’s first national adviser for LGBT+ health has said the roll-out of a highly effective HIV prevention pill could save hundreds of thousands of pounds for the country’s publicly funded health authority. In an exclusive interview Michael Brady, who will take up the role on April 1, said a planned roll-out of pre-exposure prophylaxis (PrEP) - a once-daily pill that protects against HIV – in England would prove cost effective “very quickly”.

Published
18 March 2019
From
Reuters
Obituary: Mags Portman died on February 6th

The sexual-health pioneer and campaigner for access to PrEP was 44

Published
15 March 2019
From
The Economist (requires free registration)
Jean-Michel Molina, MD, on Biomedical Failures of PrEP: Rare, But Serious

"There are multiple reasons for PrEP failures and they could be at any point in the PrEP continuum of care. From people who may not use their pills as recommended, to a health care system that is not able to provide access to PrEP for people in need, it could be also the physicians who are not ready to prescribe PrEP or not aware that they could use PrEP for preventing HIV in high-risk patients. It could be also the test that we use sometimes that are not able to detect acute HIV infection. And, if you start PrEP in someone with acute HIV infection you will see more resistance."

Published
14 March 2019
From
Contagion Live
Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say

Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle.

Published
14 March 2019
From
The New York Times
Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a different story.

Published
14 March 2019
From
FiercePharma
TAF: Quick-dissolve combination PrEP insert is effective against HIV infections in monkeys; intermittent solo pill less so

Two studies in monkeys of experimental pre-exposure prophylaxis (PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing results when presented at last week’s Conference on Retroviruses

Published
13 March 2019
By
Gus Cairns
Young Black Men at Risk for HIV Underestimate Threat

A study that started out looking at HIV risk behaviors and substance use turned into an opportunity for researchers to examine what it would take for young black men who have sex with men to try pre-exposure prophylaxis (PrEP) and stay on it.

Published
12 March 2019
From
Medscape (requires free registration)
← First12345...159Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.